美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Russell Investments Core Plus Bond ETF

24.22

-0.0228-0.09%

成交量：9

成交額：218

市值：5,679.12萬

市盈率：- -

高：24.22

開：24.24

低：24.22

收：24.24

52周最高：25.19

52周最低：24.22

股本：234.50萬

流通股本：234.50萬

量比：0.12

換手率：0.00%

股息：0.23

股息率：0.93%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

企業「出海」進階從產品輸出邁向能力輸出

480家藥企，最新營收、淨利潤來了

港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條

【券商聚焦】國投證券維持康諾亞-B（02162）買入評級指核心產品放量及BD兑現

信達生物：對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入

直擊業績會｜加科思首次實現盈利，董事長王印祥：希望通過BD在全球收穫回報

每日经济新闻

諾誠健華上半年扭虧為盈，高管強調BD會審慎篩選合作方

港股異動 | 先聲藥業(02096)早盤升逾5% 今日將發中期業績創新藥及BD收入帶動業績高增

【券商聚焦】國盛證券首予石藥集團（01093）買入評級指其創新轉型與BD出海雙輪驅動

海外BD大單落定，國產胰島素龍頭借力減重藥能否開啓新增長曲線？

全球客户「反向出差」到中國

別慌！機構資金都流向了這裏！

证券市场周刊

三筆重磅BD同日落地，創新藥出海景氣走高！T+0恒生創新藥ETF華泰柏瑞（520500）近一年累計「吸金」超25億元

白宮新聞秘書辭職；交易所BD曬12萬U提成引熱議；但斌調倉曝光；A股股民轉戰X

從「搶BD」到重現金流創新藥產業投資邏輯生變

從「搶BD」到重現金流創新藥產業投資邏輯生變

百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參

每日经济新闻

從BD高光到虧損迴歸，百利天恒面臨什麼考題？

BD交易破千億美元中國創新藥距離「全球大單品」還有多遠？

华夏时报网

BD 2026財年第三季度財報：營收增長但營業利潤下滑

TradingKey中文

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.218,"timestamp":1789502400000,"preClose":24.2408,"halted":0,"volume":9,"delay":0,"changeRate":-0.0009405630177221937,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"盤前交易","change":-0.0228,"latestTime":"09-16 07:17:26 EDT","open":24.2408,"high":24.218,"low":24.218,"amount":218,"amplitude":0,"askPrice":38.5,"askSize":100,"bidPrice":9.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":24.218,"nav":24.324847,"aum":57041766.42,"dividendRate":0.00932,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.2408,"preClose":24.218,"latestTime":"16:04 EDT","volume":2,"amount":48.436,"timestamp":1789502648572,"change":0.0228,"changeRate":0.000941,"amplitude":0},"volumeRatio":0.11508941104528424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2345000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.11508941104528424,"shares":2345000,"dividePrice":0.2257,"high":24.218,"amplitude":0,"preClose":24.2408,"low":24.218,"week52Low":24.218,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.218,"eps":0,"divideRate":0.00932,"volume":9,"delay":0,"ttmEps":0,"open":24.2408,"prevYearClose":25.08,"prevWeekClose":24.249,"prevMonthClose":24.7551,"prevQuarterClose":25.19,"fiveDayClose":24.615,"twentyDayClose":24.725},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-09-02","symbol":"BD","amount":0.104028,"announcedDate":"2026-09-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-02","defaultRemindTime":1788355800000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-04","payableDate":"2026-09-02","currency":"USD","dateTimestamp":1788321600000,"payDate":"2026-09-04"},{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"},{"executeDate":"2026-09-02","recordDate":"2026-09-02","paymentDate":"2026-09-04","value":0.104028,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667620418","title":"企業「出海」進階 從產品輸出邁向能力輸出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667620418","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667620418?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 06:58","pubTimestamp":1789513080,"startTime":"0","endTime":"0","summary":"苏州纳微科技股份有限公司董事长江必旺在回答《证券日报》记者提问时说，中国药企的海外授权合作交易爆发，不仅涉及早期项目，更覆盖技术平台、临床开发及商业化全链条，这标志着中国药企从“产品输出”向“能力输出”的跃迁。除了“出海”之外，立足自身主营业务并推进产品多元化升级，蓄力夯实企业长期发展根基也是上市公司的共识。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320971","title":"480家藥企，最新營收、淨利潤來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320971","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:39","pubTimestamp":1788867540,"startTime":"0","endTime":"0","summary":"2026年上半年，480家药企合计实现营收7,369.82亿元，同比增长+2.48%；实现归母净利润988.94亿元，同比增长+12.35%。荣昌生物营收58.53亿元，归母净利润46.62亿元，主要受海外授权合作首付款及里程碑款驱动，是板块利润暴增的最大来源。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircmeq9268445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上，近日，乐普生物发布截至2026年6月30日止六个月业绩，收入5.22亿元，同比增长12.1%；公司拥有人应占利润2739.3万元，同比下降34.4%；每股基本盈利0.02元。国联民生证券发布研报称，乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent，实现研发能力变现。在商业模式上，公司已成功构建并验证了国内商业化能力，同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动，持续优化收入结构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02157","VXUS","BK1161","KCAI","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】國投證券維持康諾亞-B（02162）買入評級 指核心產品放量及BD兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662623760?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，康诺亚-B 2026年中期实现营业收入6.17亿元人民币，同比增长24%；实现净利润12.18亿元人民币，上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日，公司现金及金融资产合计32.42亿元人民币，较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展，维持“买入-A”评级，根据DCF模型给予6个月目标价90.37港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","BD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662994764","title":"信達生物：對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2662994764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662994764?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 11:58","pubTimestamp":1787716704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662476198","title":"直擊業績會｜加科思首次實現盈利，董事長王印祥：希望通過BD在全球收穫回報","url":"https://stock-news.laohu8.com/highlight/detail?id=2662476198","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662476198?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 10:45","pubTimestamp":1787712326,"startTime":"0","endTime":"0","summary":"8月25日盘后，加科思（HK01167，股价6.000港元，市值46.93亿港元）在线上召开2026年中期业绩投资者电话会。前一晚，公司发布2026年半年报，上半年实现营业收入7.31亿元，同比增加1499.30%；实现归母净利润6.01亿元，较上年同期的-5900万元实现扭亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854332732.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854332732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738086","title":"諾誠健華上半年扭虧為盈，高管強調BD會審慎篩選合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738086","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662738086?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 17:49","pubTimestamp":1787651340,"startTime":"0","endTime":"0","summary":"“公司收入来自商业化销售叠加BD双驱动，公司对2026年持续盈利充满信心，BD（业务拓展）交易谈判会审慎筛选优质合作方。”在8月25日的2026上半年业绩说明会上，诺诚健华（9969.HK；688428.SH）联合创始人、董事长兼首席执行官崔霁松表达了上述观点。诺诚健华成立于2015年，2020年在港交所上市，2022年登陆科创板，2025年公司首次实现年度盈利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253852971124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253852971124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","BK0239","09969","688428","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477171","title":"港股異動 | 先聲藥業(02096)早盤升逾5% 今日將發中期業績 創新藥及BD收入帶動業績高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477171","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660477171?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:32","pubTimestamp":1787193141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业早盘涨超5%，截至发稿，涨4.27%，报12.69港元，成交额4017.4万港元。消息面上，先声药业将于8月21日召开2026年中期业绩发布会。主要归因于创新药收入和对外授权许可收入的增加。预计公司全年内生业务维持中报预告趋势，同时利润端受益BD继续跨越式提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","BK4585","BK1191","BK1161","159992","02096","06978","IBBQ","LNGR","MEDX","VXUS","BK1574","BK1583","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448051","title":"【券商聚焦】國盛證券首予石藥集團（01093）買入評級 指其創新轉型與BD出海雙輪驅動","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448051","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448051?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:44","pubTimestamp":1787125471,"startTime":"0","endTime":"0","summary":"国盛证券指出，公司构建“自研管线+BD出海”双轮驱动创新研发体系。通过可比公司估值法，给予公司2027年23倍PE，对应目标价13.41港元，首次覆盖给予“买入”评级。报告同时提示研发失败、产品商业化不及预期、BD里程碑收入确认节奏不确定、集采政策持续影响、估值与盈利预测假设及专利知识产权等风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BD","002670","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659421174","title":"海外BD大單落定，國產胰島素龍頭借力減重藥能否開啓新增長曲線？","url":"https://stock-news.laohu8.com/highlight/detail?id=2659421174","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659421174?lang=zh_tw&edition=fundamental","pubTime":"2026-08-16 17:05","pubTimestamp":1786871100,"startTime":"0","endTime":"0","summary":"海归博士创立的胰岛素龙头，净利润难复巅峰在凭借博凡格鲁肽获得市场高度关注之前，甘李药业最为人熟知的身份是国产胰岛素龙头。在国内三代胰岛素市场上，除诺和诺德、赛诺菲、礼来三大外企外，甘李药业市场份额最高，是国产三代胰岛素龙头。拿下海外授权许可大单，甘李药业能否迎来爆发？此次与美纳里尼的授权金额，也创出了博凡格鲁肽授权金额新高。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-08-16/doc-ininnzcn1015795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317314","title":"全球客户「反向出差」到中國","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317314","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659317314?lang=zh_tw&edition=fundamental","pubTime":"2026-08-15 22:18","pubTimestamp":1786803480,"startTime":"0","endTime":"0","summary":"在央视财经《对话》节目中，主持人陈伟鸿与几位中国科技企业的创始人聊起了一个有趣的变化：过去，中国企业出海往往意味着带着样品和销售团队满世界飞；而现在，一种相反的场景正在频繁出现——海外客户主动来中国“出差”。数据正在印证这一趋势：5月落幕的杭州第二届国际人形机器人展，累计达成合作签约56项、合作意向237项，总金额超213亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842453753.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842453753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","ROBO","AGIX","PBOT","VTHR","CHAT","KOMP","AIPO","QTOC","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"別慌！機構資金都流向了這裏！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152904?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","BK1500","07233","KURE","LU0588546209.SGD","BK1588","LU1303224171.USD","02846","BK1147","02827","CPI","LU1969619763.USD","BK4007","LU0307460666.USD","BK1574","BD","83188","03188","82846","LNGR","LU1719994722.HKD","LU1770034418.SGD","OCS","LU1251922891.USD","83130","03130","BK1161","06978","BK1583","LU0828237510.HKD","MEDX","159982","LU2328871848.SGD","LU0228659784.USD","399300","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138728","title":"三筆重磅BD同日落地，創新藥出海景氣走高！T+0恒生創新藥ETF華泰柏瑞（520500）近一年累計「吸金」超25億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138728","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138728?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 13:07","pubTimestamp":1786597620,"startTime":"0","endTime":"0","summary":"据悉，恒生创新药ETF华泰柏瑞紧密跟踪的恒生创新药指数通过QDII机制投资40家港股创新药龙头企业，主要聚焦于生物制药、化学制药及原料药等中上游创新药领域，集结了一批研发实力强劲、具备发展潜力的研发驱动型企业。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-inincxku3342998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","MEDX","06978","BK1161","BK1574","BD","LNGR","520500","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659818956","title":"白宮新聞秘書辭職；交易所BD曬12萬U提成引熱議；但斌調倉曝光；A股股民轉戰X","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818956","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818956?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:36","pubTimestamp":1786577775,"startTime":"0","endTime":"0","summary":"亲爱的读者朋友们好~\n过去24小时，X上的KOL们在聊什么呢？\n注：以下内容整理自X平台，均为个人观点，不代表本平台立场，更不构成投资建议。\n白宫新闻秘书辞职\n\n\n\n\n某交易所BD晒12W U 提成，引发争议\n\n\n\n\n但斌Q2持仓动作！\n\n\n\nA 股股民，去X上编小作文了\n\n\n\n\nTwitter：https://twitter.com/BitpushNewsCN\n比推 TG 交流群：https://t.me/BitPushCommunity\n比推 TG 订阅： https://t.me/bitpush\n\n\nKOL","market":"hk","thumbnail":"https://images.bitpush.news/2026/02/special_cn-20260213-177094771056415446.jpg:1770947697448-200x140.jpg","type":0,"news_type":0,"thumbnails":["https://images.bitpush.news/2026/02/special_cn-20260213-177094771056415446.jpg:1770947697448-200x140.jpg"],"rights":{"source":"bit_push_news","url":"https://www.bitpush.news//articles/7670356","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7670356","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_news","symbols":["BD","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186026","title":"從「搶BD」到重現金流 創新藥產業投資邏輯生變","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186026","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186026?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:26","pubTimestamp":1786577165,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","LNGR","MEDX","BD","SPHQ","06978","BK4585","159992","159399","BK1161","IBBQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186206","title":"從「搶BD」到重現金流 創新藥產業投資邏輯生變","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186206?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:15","pubTimestamp":1786576513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","MEDX","LNGR","BK4588","IBBQ","SPHQ","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","LU0320765992.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4588","LU2328871848.SGD","IE00BJJMRZ35.SGD","LU1719994722.HKD","RVMD","PTH","IE00BFTCPJ56.SGD","BK1161","LU1969619763.USD","BK4526","LU1770034418.SGD","BD","BK1500","KURE","IE0009355771.USD","BK1583","LU0109394709.USD","159938","IE0002141913.USD","ONC","LU0228659784.USD","BK1574","IE00B4R5TH58.HKD","LU1303224171.USD","BK1588","BK4139","LU0307460666.USD","CANC","09939","LU1251922891.USD","BK0239","603087","LU0828237510.HKD","IDNA","BK1515","LU0588546209.SGD","688235","BK4585","IE0009354923.USD","BBH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986658","title":"從BD高光到虧損迴歸，百利天恒面臨什麼考題？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986658","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658986658?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 15:49","pubTimestamp":1786348144,"startTime":"0","endTime":"0","summary":"相对于坎坷的赴港闯关之路，在生物科技这条赛道上，百利天恒已有产品实现商业化。从项目成熟度看，百利天恒并非停留在“早期研发概念验证”阶段。盈利高峰来自授权兑现，亏损继续扩大百利天恒最容易抓住眼球的，是其利润表在近两年出现过明显波动。这组数据本身已经足够说明，百利天恒并不是一家已经进入稳定盈利通道的创新药企业。从这个角度看，百利天恒的长板与短板都很鲜明。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786328428501757201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BD","688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658792716","title":"BD交易破千億美元 中國創新藥距離「全球大單品」還有多遠？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658792716","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658792716?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 12:36","pubTimestamp":1786250165,"startTime":"0","endTime":"0","summary":"8月5日，上海。2026沙利文峰会生命科学新投资高峰论坛上，一组数据让在场者屏息：2026年上半年，中国创新药对外授权（License-out）交易潜在总额达1100亿美元，交易规模达到2025年全年的八成。全球Top10BD交易中，中国独占8席。八年前，当港交所18A章刚刚落地时，中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835903315.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835903315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680386","title":"BD 2026財年第三季度財報：營收增長但營業利潤下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680386","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:42","pubTimestamp":1786012961,"startTime":"0","endTime":"0","summary":"BD 2026财年第三季度营收49.83亿美元，同比增长5.4%；持续经营稀释EPS为1.64美元，增长4.5%。营业利润下降10.3%，调整后EPS指引下限上调。","market":"sg","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/trader1.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/trader1.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262082575-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BD","PSET","SQMX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}